Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 749

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 749
---
 Nasdaq. D. Selling Shareholders Not applicable. E. Dilution Not applicable. F. Expenses of the Issue Not applicable. ITEM 10. ADDITIONAL INFORMATION A. Share Capital Not applicable. B. Memorandum and Articles of Association A copy of our amended and restated articles of association is attached as Exhibit 1.1 to this annual report. The information called for by this Item is set forth in Exhibit 2(d) to this annual report and is incorporated by reference into this annual report. Annex F-94 C. Material Contracts The following is a summary of each material contract, other than material contracts entered into in the ordinary course of business, to which we are or have been a party, for the two years immediately preceding the date of this annual report: •ATM Sales Agreement, dated March4, 2022 by and between NLS Pharmaceutics Ltd. and Virtu Americas LLC. See Item 5. “Operating and Financial Review and Prospects — Recent Financing Agreements” for more information about this document. •Securities Purchase Agreement, dated April13, 2022, by and between NLS Pharmaceutics Ltd. and District 2 Capital Fund LP, Armistice Master Capital Fund Ltd., Ronald Hafner, and Lincoln Park Capital Fund LLC. See Item 5. “Operating and Financial Review and Prospects — Recent Financing Agreements” for more information about this document. •Placement Agent Agreement, dated April13, 2022, by and between NLS Pharmaceutics Ltd. and A.G.P./Alliance Global Partners. See Item 5. “Operating and Financial Review and Prospects — Recent Financing Agreements” for more information about this document. •Short Term Note Agreement, dated August19, 2022 by and between NLS Pharmaceutics Ltd. and Ronald Hafner, Michael Stein, Jürgen Bauer, Maria Nayvalt and Gian -MarcoRinaldi. See Item 5. “Operating and Financial Review and Prospects — Recent Financing Agreements” for more information about this document. •Securities Purchase Agreement, dated September30, 2022 by and between NLS Pharmaceutics Ltd. and George Apostol, Ronald Hafner, Felix Grisard, Jurgen Bauer and Maria Nayvalt. See Item 5. “Operating and Financial Review and Prospects — Recent Financing Agreements” for more information about this document. •Securities Purchase Agreement, dated December6, 2022 by